Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 45 publications
Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial.
Journal: JAMA oncology
Published: July 30, 2026
Camizestrant in combination with capivasertib for women with ER-positive, HER2-negative advanced breast cancer: results from SERENA-1.
Journal: ESMO open
Published: October 27, 2025
Staging Invasive Lobular Carcinoma: A Prospective Study on the Efficacy of 18F-Fluoroestradiol (FES)-PET/CT.
Journal: Clinical breast cancer
Published: August 02, 2025
Liquid Biopsy Approaches for Cancer Characterization, Residual Disease Detection, and Therapy Monitoring.
Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Published: April 30, 2025
Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2- Advanced Breast Cancer: Results from SERENA-1.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 04, 2025
Multiplex Spatial Proteomic Analysis of HER2-Positive Breast Tumors Reveals Unique Molecular and Immunologic Features Associated With Treatment Response.
Journal: JCO precision oncology
Published: April 03, 2025
Phase 1/2 study of H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive, HER2-negative breast cancer.
Journal: Breast cancer research : BCR
Published: March 04, 2025
Real-World Studies and Randomized Controlled Trials: A Podcast Discussion of the Relative Strengths and Limitations of These Complementary Designs for Cancer Research.
Journal: Oncology and therapy
Published: December 24, 2024
A composite 18F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026).
Journal: Breast (Edinburgh, Scotland)
Published: November 04, 2024
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
Journal: Nature medicine
Published: August 07, 2024
TOWARDS Study: Patient-Derived Xenograft Engraftment Predicts Poor Survival in Patients With Newly Diagnosed Triple-Negative Breast Cancer.
Journal: JCO precision oncology
Published: July 29, 2024
Last Updated: 09/26/2026